Federal Register / Vol. 82, No. 214 / Tuesday, November 7, 2017 / Notices 51637 

include patients with clinical or 

laboratory evidence of chronic hepatitis 

C disease, such as the presence of 

fibrosis by biopsy or noninvasive tests. 

• Additional details on DAA drug 

development in patients with 

decompensated cirrhosis, including 

recommendations for a review by an 

independent adjudication committee for 

all serious hepatic events, deaths, liver 

transplantations, and changes in 

prespecified alanine transaminase, 

aspartate transaminase, and bilirubin 

parameters and a recommendation for 

long-term followup to characterize 

clinical outcomes such as progression or 

regression of liver disease, liver-related 

mortality, occurrence of hepatocellular 

carcinoma, or liver failure requiring 

liver transplantation. 

• Additional clarification on efficacy 

endpoints, specifically additional posttreatment followup (e.g., 1 year or 

longer) may be needed if one or more 

drugs in the regimen has a long plasma 

or intracellular half-life or prolonged 

antiviral activity. 

This guidance is being issued 

consistent with FDA’s good guidance 

practices regulation (21 CFR 10.115). 

The guidance represents the current 

thinking of FDA on ‘‘Chronic Hepatitis 

C Virus Infection: Developing DirectActing Antiviral Drugs for Treatment.’’ 

It does not establish any rights for any 

person and is not binding on FDA or the 

public. You can use an alternative 

approach if it satisfies the requirements 

of the applicable statutes and 

regulations. This guidance is not subject 

to Executive Order 12866. 

II. The Paperwork Reduction Act of 

1995 

This guidance refers to previously 

approved collections of information that 

are subject to review by the Office of 

Management and Budget (OMB) under 

the Paperwork Reduction Act of 1995 

(44 U.S.C. 3501–3520). The collections 

of information in 21 CFR parts 312 and 

314 have been approved under OMB 

control numbers 0910–0014 and 0910– 

0001, respectively. 

III. Electronic Access 

Persons with access to the internet 

may obtain the guidance at either 

https://www.fda.gov/Drugs/Guidance

ComplianceRegulatoryInformation/

Guidances/default.htm or https://

www.regulations.gov. 

Dated: November 2, 2017. 

Anna K. Abram, 

Deputy Commissioner for Policy, Planning, 

Legislation, and Analysis. 

[FR Doc. 2017–24195 Filed 11–6–17; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following Heart, Lung, & Blood Program 

Project Review Committee meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Heart, Lung, and 

Blood Initial Review Group; Heart, Lung, and 

Blood Program Project Review Committee. 

Date: December 1, 2017. 

Time: 8:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Sheraton BWI (Baltimore), 1100 Old 

Elkridge Landing Road, Baltimore, MD 

21090. 

Contact Person: Jeffrey H. Hurst, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6701 Rockledge Drive, Room 7208, Bethesda, 

MD 20892, 301–435–0303, hurstj@

nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: November 1, 2017. 

Michelle Trout, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–24144 Filed 11–6–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR Panel: 

Synthetic Psychoactive Drugs and Strategic 

Approaches to Counteract their Deleterious 

Effects. 

Date: November 30, 2017. 

Time: 1:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Jasenka Borzan, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4214, 

MSC 7814, Bethesda, MD 20892–7814, 301– 

435–1787, borzanj@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Neuroimmunology, 

Neuroinflammation and Brain Tumor. 

Date: December 6, 2017. 

Time: 10:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Nataliya Gordiyenko, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5202, 

MSC 7846, Bethesda, MD 20892, 301–435– 

1265, gordiyenkon@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Retinal Synapses and Circuitry. 

Date: December 6, 2017. 

Time: 12:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Afia Sultana, Ph.D., 

Scientific Review Officer, National Institutes 

of Health, Center for Scientific Review, 6701 

Rockledge Drive, Room 4189, Bethesda, MD 

20892, (301) 827–7083, sultanaa@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 


ethrower on DSK3G9T082PROD with NOTICES
51638 Federal Register / Vol. 82, No. 214 / Tuesday, November 7, 2017 / Notices 

Dated: November 1, 2017. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–24143 Filed 11–6–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOUSING AND 

URBAN DEVELOPMENT 

[Docket No. FR–6045–N–01] 

Annual Indexing of Basic Statutory 

Mortgage Limits for Multifamily 

Housing Programs 

AGENCY: Office of the Assistant 

Secretary for Housing—Federal Housing 

Commissioner, HUD. 

ACTION: Notice. 

SUMMARY: In accordance with Section 

206A of the National Housing Act, HUD 

has adjusted the Basic Statutory 

Mortgage Limits for Multifamily 

Housing Programs for Calendar Year 

2017. 

DATES: January 1, 2017. 

FOR FURTHER INFORMATION CONTACT: 

Daniel J. Sullivan, Deputy Director, 

Office of Multifamily Development, 

Department of Housing and Urban 

Development, 451 Seventh Street SW., 

Washington, DC 20410–8000, telephone 

(202) 402–6130 (this is not a toll-free 

number). Hearing or speech-impaired 

individuals may access this number 

through TTY by calling the toll-free 

Federal Information Relay Service at 

(800) 877–8339. 

SUPPLEMENTARY INFORMATION: The FHA 

Down Payment Simplification Act of 

2002 (Pub. L. 107–326, approved 

December 4, 2002) amended the 

National Housing Act by adding a new 

Section 206A (12 U.S.C. 1712a). Under 

Section 206A, the following are affected: 

I. Section 207(c)(3)(A) (12 U.S.C. 

1713(c)(3)(A)); 

II. Section 213(b)(2)(A) (12 U.S.C. 

1715e(b)(2)(A)); 

III. Section 220(d)(3)(B)(iii)(I) (12 U.S.C. 

1715k(d)(3)(B)(iii)(I)); 

IV. Section 221(d)(4)(ii)(I) (12 U.S.C. 

1715l(d)(4)(ii)(I)); 

V. Section 231(c)(2)(A) (12 U.S.C. 

1715v(c)(2)(A)); and 

VI. Section 234(e)(3)(A) (12 U.S.C. 

1715y(e)(3)(A)). 

The Dollar Amounts in these sections 

are the base per unit statutory limits for 

FHA’s multifamily mortgage programs 

collectively referred to as the ‘Dollar 

Amounts.’ They are adjusted annually 

(commencing in 2004) on the effective 

date of the Consumer Financial 

Protection Bureau’s adjustment of the 

$400 figure in the Home Ownership and 

Equity Protection Act of 1994 (HOEPA) 

(Pub. L. 103–325, approved September 

23, 1994). The adjustment of the Dollar 

Amounts shall be calculated using the 

percentage change in the Consumer 

Price Index for All Urban Consumers 

(CPI–U) as applied by the Bureau of 

Consumer Financial Protection for 

purposes of the above-described HOEPA 

adjustment. 

HUD has been notified of the 

percentage change in the CPI–U used for 

the HOEPA adjustment and the effective 

date of the HOEPA adjustment. The 

percentage change in the CPI–U is 2.1 

percent and the effective date of the 

HOEPA adjustment is January 1, 2017. 

The Dollar Amounts have been adjusted 

correspondingly and have an effective 

date of January 1, 2017. 

These revised statutory limits, high 

cost areas and per unit cost thresholds 

for substantial rehabilitation may be 

applied to FHA multifamily mortgage 

insurance applications submitted or 

amended on or after July 1, 2017, so 

long as the loan has not been initially 

endorsed. 

The adjusted Dollar Amounts for 

Calendar Year 2017 are shown below: 

Basic Statutory Mortgage Limits for 

Calendar Year 2017 

Multifamily Loan Program 

Section 207—Multifamily Housing 

Section 207 pursuant to Section 223(f)— 

Purchase or Refinance Housing 

Section 220—Housing in Urban 

Renewal Areas 

Bedrooms Non-elevator Elevator 

0 ................ $51,575 $60,158 

1 ................ 57,133 66,657 

2 ................ 68,244 81,734 

3 ................ 84,116 102,368 

4+ .............. 95,228 115,749 

Section 213—Cooperatives 

Bedrooms Non-elevator Elevator 

0 ................ $55,894 $59,515 

1 ................ 64,447 67,428 

2 ................ 77,725 81,993 

3 ................ 99,489 106,073 

4+ .............. 110,837 116,438 

Section 234—Condominium Housing 

Bedrooms Non-elevator Elevator 

0 ................ $57,035 $60,021 

1 ................ 65,762 68,806 

2 ................ 79,311 83,667 

3 ................ 101,521 108,239 

4+ .............. 113,098 118,812 

Section 221(d)(4)—Moderate Income 

Housing 

Bedrooms Non-elevator Elevator 

0 ................ $51,328 $55,445 

1 ................ 58,266 63,562 

2 ................ 70,429 77,291 

3 ................ 88,400 99,988 

4+ .............. 99,890 109,758 

Section 231—Housing for the Elderly 

Bedrooms Non-elevator Elevator 

0 ................ $48,800 $55,445 

1 ................ 54,555 63,562 

2 ................ 65,147 77,291 

3 ................ 78,401 99,988 

4+ .............. 92,173 109,758 

Section 207—Manufactured Home Parks 

Per Space—$23,678 

Per Unit Limit for Substantial 

Rehabilitation for Calendar Year 2017 

The 2016 Multifamily Accelerated 

Processing (MAP) Guide established a 

base amount of $15,000 per unit to 

define substantial rehabilitation for FHA 

insured loan programs. Section 5.1.D.2 

of the MAP guide requires that this base 

amount be adjusted periodically based 

on the percentage change published by 

the Consumer Financial Protection 

Bureau or other inflation cost index 

published by HUD. Accordingly, the 

2017 base amount per dwelling unit to 

determine substantial rehabilitation for 

FHA insured loan programs is $15,315. 

Environmental Impact 

This issuance establishes mortgage 

and cost limits that do not constitute a 

development decision affecting the 

physical condition of specific project 

areas or building sites. Accordingly, 

under 24 CFR 50.19(c)(6), this notice is 

categorically excluded from 

environmental review under the 

National Environmental Policy Act of 

1969 (42 U.S.C. 4321). 

Dated: October 31, 2017. 

Dana T. Wade, 

General Deputy Assistant Secretary for 

Housing. 

[FR Doc. 2017–24171 Filed 11–6–17; 8:45 am] 

BILLING CODE 4210–67–P 


ethrower on DSK3G9T082PROD with NOTICES